The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Whitaker, Hayley C ^a   Kote Jarai, Zsofia ^b,c   Ross Adams, Helen ^a   Warren, Anne Y ^d   Burge, Johanna ^a   George, Anne ^a   Bancroft, Elizabeth ^b,c   Jhavar, Sameer ^b,c   Leongamornlert, Daniel ^b,c   Tymrakiewicz, Malgorzata ^b,c   Saunders, Edward ^b,c   Page, Elizabeth ^b,c   Mitra, Anita ^b,c   Mitchell, Gillian ^e   Lindeman, Geoffrey J ^f   Evans, D Gareth ^g   Blanco, Ignacio ^h   Mercer, Catherine ⁱ   Rubinstein, Wendy S ^j   Clowes, Virginia ^d   Douglas, Fiona ^k   Hodgson, Shirley ^l   Walker, Lisa ^m   Donaldson, Alan ⁿ   Izatt, Louise ^o   Dorkins, Huw ^p   Male, Alison ^q   Tucker, Kathy ^r   Stapleton, Alan ^s   Lam, Jimmy ^s   Kirk, Judy ^t   Lilja, Hans ^u   Easton, Douglas ^v   Cooper, Colin ^b,c   Eeles, Rosalind ^b,c   Neal, David E ^a   more..

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ PRINCESS ANNE HOSPITAL   (United Kingdom)

^j NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^m CHURCHILL HOSPITAL   (United Kingdom)

ⁿ ST MICHAEL'S HOSPITAL   (United Kingdom)

^o GUY S HOSPITAL   (United Kingdom)

^p NORTHWICK PARK HOSPITAL   (United Kingdom)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

^r PRINCE OF WALES HOSPITAL   (Australia)

^s REPATRIATION GENERAL HOSPITAL   (Australia)

^t WESTMEAD HOSPITAL   (Australia)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; BETA-MICROSEMINOPROTEIN; PROSTATIC SECRETORY PROTEIN; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONSET AGE; PENETRANCE; PHENOTYPE; PROCESS DEVELOPMENT; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; BLOOD; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PROSTATE TUMOR; URINE;

ALLELES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 78149451143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013363     Document Type: Article

References (32)

1. Lilja H, Abrahamsson PA (1988) Three predominant proteins secreted by the human prostate gland. Prostate 12: 29-38.
2. Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, et al. (2000) PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 164: 1819-1824.
3. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, et al. (2006) A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 175: 1291-1297.
4. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, et al. (1999) Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 38: 278-284.
5. Kwong J, Xuan JW, Choi HL, Chan PS, Chan FL (2000) PSP94 (or betamicroseminoprotein) is a secretory protein specifically expressed and synthesized in the lateral lobe of the rat prostate. Prostate 42: 219-229.
6. Thota A, Karajgikar M, Duan W, Gabril MY, Chan FL, et al. (2003) Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins. J Cell Biochem 88: 999-1011.
7. Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, et al. (2002) Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 9: 1589-1599.
8. Gabril M, Xuan J, Moussa M, Dinney CP, Chin JL, et al. (2004) Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology 64: 1233-1237.
9. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, et al. (2005) Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics 21: 650-659.
10. Xuan JW, Wu D, Guo Y, Garde S, Baijal-Gupta M, et al. (1997) Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I). Immuno-dominant and immuno-recessive area. J Cell Biochem 65: 172-185.
11. von der Kammer H, Krauhs E, Aumuller G, Scheit KH (1990) Characterization of a monoclonal antibody specific for prostatic secretory protein of 94 amino acids (PSP94) and development of a two-site binding enzyme immunoassay for PSP94. Clin Chim Acta 187: 207-219.
12. Doctor VM, Sheth AR, Simha MM, Arbatti NJ, Aaveri JP, et al. (1986) Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: comparison of its distribution in normal, benign and malignant prostates. Br J Cancer 53: 547-554.
13. Weiber H, Andersson C, Murne A, Rannevik G, Lindstrom C, et al. (1990) Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. Am J Pathol 137: 593-603.
14. Baijal-Gupta M, Clarke MW, Finkelman MA, McLachlin CM, Han VK (2000) Prostatic secretory protein (PSP94) expression in human female reproductive tissues, breast and in endometrial cancer cell lines. J Endocrinol 165: 425-433.
15. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316-321.
16. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40: 310-315.
17. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, et al. (2009) Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate.
18. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, et al. (2009) Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet.
19. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, et al. (2009) Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A 106: 7933-7938.
20. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, et al. (1999) In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 41: 99-109.
21. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK, et al. (1998) Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 35: 109-116.
22. Vanaja DK, Cheville JC, Iturria SJ, Young CY (2003) Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63: 3877-3882.
23. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, et al. (2007) Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 13: 4130-4138.
24. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA (2003) Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 63: 2072-2078.
25. Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, et al. (2006) A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer 118: 2350-2358.
26. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE (2009) The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate.
27. Ploussard G, de la Taille A (2010) Urine biomarkers in prostate cancer. Nat Rev Urol 7: 101-109.
28. Bolduc S, Lacombe L, Naud A, Gregoire M, Fradet Y, et al. (2007) Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 1: 377-381.
29. Mitra AV, Bancroft EK, Eeles RA (2007) A review of targeted screening for prostate cancer: introducing the IMPACT study. BJU Int 99: 1350-1355.
30. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692-695.
31. Foster C, Watson M, Eeles R, Eccles D, Ashley S, et al. (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br J Cancer 96: 718-724.
32. Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM (2006) Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 12: 6018-6022.